Amgen Inc ($AMGN) announced an update on their ongoing clinical study. Amgen Extends Pediatric Psoriasis Study: What ...

In the second half of his Maui Derm recap, George Martin, MD, founder and program director of the meeting, highlights new ...

Oral roflumilast showed potential as a nonbiologic systemic therapy for moderate to severe psoriasis, offering an alternative ...

SNGX READ THE FULL SNGX RESEARCH REPORT Business Update Positive Results for SGX302 in Cohort 3 of Phase 2a Psoriasis Trial ...

Back in October, the 2025 Fall Clinical Dermatology Conference showcased some of the most exciting advances in skin disease treatment this year. From pill-based TYK2 inhibitors and durable IL-23 ...

Johnson & Johnson JNJ announced that the European Commission (EC) has approved an expanded use of its blockbuster psoriasis ...

The results position Takeda, which acquired its therapy in one of the industry’s larger single-drug acquisitions, to ...

Soligenix, Inc. (Nasdaq: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an unmet ...

Patients with moderate-to-severe plaque psoriasis who took the once-daily pill showed significantly clearer skin compared with those on placebo or the existing therapy apremilast, the company said.

Psoriasis is a lifelong condition that comes and goes in flares, and the key to managing it is the right treatment. Your dermatologist will help you find a therapy based on: How bad your symptoms are ...

Itchy, flaky psoriasis is never fun, but it can also sometimes be downright painful. Working with your derm to find the right treatment option is crucial, but with so many potential options to choose ...

Ear psoriasis is a chronic – meaning ongoing – skin condition that happens when your immune system reacts too strongly to protect against germs and other invaders. This causes dead skin cells to build ...